Resources

Type of publications
Regions
Diseases

5255 results found

2023 ∙ Malone, Shelia M. Mitra, Amal K. Onumah, Nwanne A. Brown, Alexis Jones, Lena M. Tresvant, Da'Chirion Brown, Cagney S. Onyia, Austine U. Iseguede, Faith O.

Safety and Efficacy of Post-Eradication Smallpox Vaccine as an Mpox Vaccine: A Systematic Review with Meta-Analysis

  • Adults
  • Mpox
  • Safety
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Wilson, Lydia Gracie, Lara Kidy, Farah Thomas, G. Neil Nirantharakumar, Krishnarajah Greenfield, Sheila Manaseki-Holland, Semira Ward, Derek J. Gooden, Tiffany E.

Safety and efficacy of tuberculosis vaccine candidates in low- and middle-income countries: a systematic review of randomised controlled clinical trials

  • Newborn
  • Adolescents
  • Adults
  • Low and Middle Income Countries
  • Tuberculosis
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Hu, Y. Wang, Y. Shao, T. Tang, W. Hu, K. Zhou, Y. Miao, L. Liu, J. Wang, B. Yu, W.

Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes

  • Adults
  • Older adults
  • COVID-19
  • Safety
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Fan, X. Zhao, Y. Wu, F. Yuan, Y. Lang, B. Yin, D. Xu, Z. Jiang, S. Zou, H. Yuan, J. Sun, C.

Safety and Immunogenicity of SARS-CoV-2 Vaccines in People Living with HIV: A Systematic Review and Meta-analysis of Real-World Studies

  • Adults
  • Older adults
  • COVID-19
  • Safety
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Kandeel, M. Morsy, M. A. Abd El-Lateef, H. M. Marzok, M. El-Beltagi, H. S. Al Khodair, K. M. Albokhadaim, I. Venugopala, K. N.

Safety and immunogenicity of the ChAdOx1, MVA-MERS-S, and GLS-5300 DNA MERS-CoV vaccines

  • Adults
  • COVID-19
  • Efficacy/effectiveness
  • Safety
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Piché-Renaud, P. P. Yue Lee, E. Ji, C. Qing Huang, J. Y. Uleryk, E. Teoh, C. W. Morris, S. K. Top, K. A. Upton, J. E. M. Vyas, M. V. Allen, U. D.

Safety and immunogenicity of the live-attenuated varicella vaccine in pediatric solid organ transplant recipients: A systematic review and meta-analysis

  • Newborn
  • Children
  • Adolescents
  • Adults
  • Varicella
  • Safety
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Low
2023 ∙ Stefanou, M. I. Palaiodimou, L. Theodorou, A. Christodoulou, M. V. Tzartos, J. S. Tzanetakos, D. Kitsos, D. Chondrogianni, M. Zouvelou, V. Dardiotis, E. Tzavellas, E. Syrigou, E. Benetou, V. Paraskevas, G. P. Tsiodras, S. Tsivgoulis, G. Giannopoulos, S.

Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis

  • All age groups
  • COVID-19
  • Safety
Methodological quality (AMSTAR 2):
Moderate
2023 ∙ Wolfe, D. M. Fell, D. Garritty, C. Hamel, C. Butler, C. Hersi, M. Ahmadzai, N. Rice, D. B. Esmaeilisaraji, L. Michaud, A. Soobiah, C. Ghassemi, M. Khan, P. A. Sinilaite, A. Skidmore, B. Tricco, A. C. Moher, D. Hutton, B.

Safety of influenza vaccination during pregnancy: a systematic review

  • Pregnant women
  • Influenza
  • Safety
Methodological quality (AMSTAR 2):
High
2023 ∙ van de Pol, N. Pan, Q. Derikx, Laap Bakker, L. van der Woude, C. J. de Vries, A. C.

SARS-CoV-2 breakthrough infections after COVID-19 vaccination in patients with inflammatory bowel disease: a systematic review and meta-analysis

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Liang, Y. Sun, Q. Liu, Q. Pang, Y. Tang, S.

SARS-CoV-2 incidence, seroprevalence, and COVID-19 vaccination coverage in the homeless population: a systematic review and meta-analysis

  • All age groups
  • COVID-19
  • Coverage
Methodological quality (AMSTAR 2):
Not applicable
Loading...